Cornell University

The Scripps Research Institute

International Aids Vaccine Initiative

Progenics Pharmaceuticals, Inc.

Albert Cupo

John S Moore

Andre Marozsan

William C Olson

Naoya Tsurushita

Shankar Kumar

C Richter King

Dangshe Ma

Ian A Wilson

Andrew B Ward

Simon Hoffenberg

Gerald P Donovan

Rogier W Sanders

Michael P Caulfield

Rogier Sanders

Yun Kang

Andre J Marozsan

Hansi Dean

P J Klasse

Jean-Philippe Julien

Kirsten Nagashima

Brian Kennedy

Per Johan Klasse

Michael Caulfield

Jean-Phillippe Julien

John Moore

Expression vectors and mammalian cell lines containing them are described that enable the recombinant production of HIV-1 envelope proteins, including SOSIP modified gp140 trimers capable of inducing broadly neutralizing antibodies.

Materials and methods for producing cleaved, HIV-1 envelope glycoprotein trimers

The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron microscopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention.

HIV-1 envelope glycoprotein

Provided herein are reagents, compositions, and therapies with which to treatinfection and related disease conditions and pathologies, such as-associated diarrhea, resulting from infection bybacteria and the enterotoxins produced by these bacteria. In particular, antibodies or antigen-binding fragments thereof that bind specifically to toxin A and/or toxin B ofand neutralize the activities of these toxins; compositions comprising such antibodies; and methods of using the antibodies and the compositions are provided.

[object Object]

Growing community of inventors

Stamford, CT, United States of America

Albert Cupo